Early Remission at 6 Months as a Predictor of Longterm Remission in New Onset Rheumatoid Arthritis

Emilie SAPART¹, Tatiana SOKOLOVA², Aleksandra AVRAMOVSKA¹, Paschalis SIDIRAS³, Sandra KLEIMBERG³, Stéphanie DIERCKX⁴, Laurent MERIC de BELLEFON⁵, Clio RIBBENS⁶, Michel MALAISE⁶, Silvana DI ROMANA⁷, Valérie BADOT⁸ and Patrick DUREZ⁹, ¹Rhumatologie, cliniques universitaires saint-luc, Université catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Rhumatologie, Hôpital Erasme, Brussels, Belgium, ⁴Rhumatologie, CHU UCL Mont-Godinne, Brussels, Belgium, ⁵Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁶Rhumatologie, CHU de Liège, Liège, Belgium, ⁷Rhumatologie, CHU Saint–Pierre, Brussels, Belgium, ⁸Rhumatologie, CHU Brugmann, Brussels, Belgium, ⁹Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium

Meeting: ACR Convergence 2021

Keywords: rheumatoid arthritis

Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Early therapeutic intervention is crucial for patients with early rheumatoid arthritis (ERA). The goal of remission is achievable in a large proportion of ERA patients.

To evaluate the rate of patients in remission at 6 months and to correlate the 36 and 60 months remission rate in the Belgian CAP48 cohort and the UCLouvain Brussels cohort. To identify baseline characteristics differences between patients achieving remission or not.

Methods: We included patients with ERA from the CAP48 cohort and from the UCLouvain Brussels cohort who met the ACR/EULAR 2010 RA classification criteria. All patients were naïve to csDMARDs therapy. We collected patient characteristics at baseline and clinical response was analysed at 6, 36 and 60 months.

Results: 287 RA patients from our UCLouvain Brussels Cohort and the CAP48 cohort were analysed (211 Females, 76 Males, mean age 46.2 years, 43.4% with baseline erosion, 70.1% with ACPA, 70.3% with Rheumatoid Factor, mean HAQ 1.16, mean DAS28-CRP 4.67, mean SDAI 24.9 and mean CDAI 24.1).

The clinical results are summarized in the Table.

We divided the patients according to whether they achieved remission DAS28-CRP < 2.6 (group 1), or not (group 2) at 6 months.

Patient baseline characteristics were similar in the two groups respectively: age (46.7 vs 45.4 yrs); female (68.5 vs 77.3%); smoker (25.6 vs 27.0%); ACPA positive (70.1 vs 75.4%); baseline X-ray erosion (45.0 vs 54.7%).

DAS28-CRP, SDAI and CDAI at 6 months could predict long-term remission at 36 and 60 months (Figure).

In group 1 global remission (DAS28-CRP< 2.6, HAQ< 0.5 and no X-ray progression) was observed in 75.6% at 60 months. The majority of these patients (69.4%) are still treated with Methotrexate, the others were treated with combination therapy.

Conclusion: Early and long term remission is an achievable goal in our two cohorts. Early diagnosis is critical in standard of care. At 6 months, all remission index criteria are good predictor for long term remission and could be used in daily care.

Table1

Figure1

Disclosures: E. SAPART, None; T. SOKOLOVA, None; A. AVRAMOVSKA, None; P. SIDIRAS, None; S. KLEIMBERG, None; S. DIERCKX, None; L. MERIC de BELLEFON, None; C. RIBBENS, None; M. MALAISE, None; S. DI ROMANA, None; V. BADOT, None; P. DUREZ, Bristol-Myers Squibb, 6, Sanofi, 6, Eli Lilly, 6, Celltrion, 6.

To cite this abstract in AMA style:

SAPART E, SOKOLOVA T, AVRAMOVSKA A, SIDIRAS P, KLEIMBERG S, DIERCKX S, MERIC de BELLEFON L, RIBBENS C, MALAISE M, DI ROMANA S, BADOT V, DUREZ P. Early Remission at 6 Months as a Predictor of Longterm Remission in New Onset Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/early-remission-at-6-months-as-a-predictor-of-longterm-remission-in-new-onset-rheumatoid-arthritis/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-remission-at-6-months-as-a-predictor-of-longterm-remission-in-new-onset-rheumatoid-arthritis/